Evidence map›Paper›PMID 35286328›Full record

ArticlePloS one2022

SARS-CoV-2 seroprevalence in the city of Puerto Madryn: Underdiagnosis and relevance of children in the pandemic.

Daniel Schonfeld, Hugo Fernández, Julio Ramírez, Denisse Acosta, Julián Becerra, Magali Wettstein, Teresa Strella, Marcelo Vaccaro, Sergio Arias, Vilma Rodríguez Calvo and 2 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Dynamics of SARS-CoV-2 seroassay sensitivity: a systematic review and modelling study.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2023
    Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Daniel SchonfeldCentro Diagnostico San Jorge, Puerto Madryn, Chubut, Argentina.
Hugo FernándezInstituto Nacional de Enfermedades Respiratorias "Dr. Emilio Coni", Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbran", Santa Fe, Argentina.
Julio RamírezSchool of Medicine Louisville, Louisville, Kentucky, United States of America.
Denisse AcostaHospital de Puerto Madryn, Puerto Madryn, Chubut, Argentina.
Julián BecerraSubsecretaria de Atención Primaria, Puerto Madryn, Chubut, Argentina.
Magali WettsteinInstituto Nacional de Enfermedades Respiratorias "Dr. Emilio Coni", Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbran", Santa Fe, Argentina.ORCID 0000-0002-1177-359X
Teresa StrellaEpidemiologia del Ministerio de Salud, Rawson, Chubut, Argentina.
Marcelo VaccaroSubsecretaria de Atención Primaria, Puerto Madryn, Chubut, Argentina.
Sergio AriasInstituto Nacional de Enfermedades Respiratorias "Dr. Emilio Coni", Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbran", Santa Fe, Argentina.ORCID 0000-0002-1178-4299
Vilma Rodríguez CalvoHospital de Puerto Madryn, Puerto Madryn, Chubut, Argentina.
Roberto NemeSubsecretaria de Atención Primaria, Puerto Madryn, Chubut, Argentina.
Daniel Pérez-ChadaUniversidad Austral, Hospital Universitario Austral, Pulmonary Medicine, Pilar, Argentina.ORCID 0000-0002-0836-9641
Centro Científico Tecnológico Patagónico · ARAdministración Nacional de Laboratorios e Institutos de Salud · ARAustral University · ARMinisterio de Salud · AR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundReported cases of COVID-19 may be underestimated due to mild or asymptomatic cases and a low testing rate in the general population. RESEARCH QUESTION: What is the seroprevalence of SARS-CoV-2 infection in the general population and how it compares with the data on SARS-CoV-2 cases reported by a national health surveillance system (SNVS 2.0). STUDY DESIGN AND

methodsThis was a population-based, seroepidemiological, cross-sectional study in the city of Puerto Madryn, a middle size city in the Province of Chubut, Argentina. The study period was between March 3 and April 17, 2021. The sample size was calculated using the technique of calculation of confidence intervals for a proportion. Participants were selected using stratified and cluster probability sampling. A total of 1405 subjects were invited to participate in the study. Participants were divided into the following four age groups: 1) 0 to 14, 2) 15 to 39, 3) 40 to 64, and 4) 65 or older. After informed consent was obtained, a blood sample was taken by puncture of the fingertip, and a structured questionnaire was administered to evaluate demographics, socioeconomic status, level of education, comorbidities and symptoms suggestive of COVID-19. COVID-19 seroprevalence was documented using an immunoenzymatic test for the in vitro detection of IgG antibodies specific to the spike protein of SARS-CoV-2.

resultsA total of 987 participants completed the survey. Seropositivity in the full study population was 39,2% and in those under 15 years of age, 47.1%. Cases reported by the SNSV 2.0 amounted to 9.35% of the total population and 1.4% of those under 15 years of age.

interpretationThe prevalence of COVID-19 infection in the general population is four times higher than the number of cases reported by the SNVS 2.0 in the city of Puerto Madryn. For each child under the age of 15 identified by the SNVS 2.0 with COVID-19, there are more than 30 unrecognized infections. Seroepidemiological studies are important to define the real extent of SARS-CoV-2 infection in a particular community. Children may play a significant role in the progression of the current pandemic.

Indexed as

AdolescentAdultAgedAge DistributionAntibodies, ViralArgentinaChildChild, PreschoolCOVID-19Cross-Sectional StudiesFemaleHumansImmunoglobulin GInfantInfant, NewbornMaleAntibodies, ViralImmunoglobulin GSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2

Identifiers

PMID35286328
PMCPMC8920177
OpenAlexW4221136538

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.